{"id":"gitoformate","rwe":[{"pmid":"3449065","year":"1987","title":"[Postprandial delay of drug absorption in a gitoformate model].","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"6542412","year":"1984","title":"[Plasma levels of gitoxin (by RIA and rubidium-86 uptake) and systolic time after treatment with a single dose of gitoformate].","finding":"","journal":"Cardiologia (Rome, Italy)","studyType":"Clinical Study"},{"pmid":"6541927","year":"1984","title":"[Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency].","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"7185409","year":"1981","title":"[Pharmacokinetics and pharmacodynamics of gitoformate in subjects with atrial fibrillation].","finding":"","journal":"Bollettino della Societa italiana di cardiologia","studyType":"Clinical Study"},{"pmid":"7185408","year":"1981","title":"[Pharmacokinetics of gitoformate in subjects with renal insufficiency under dialysis treatment].","finding":"","journal":"Bollettino della Societa italiana di cardiologia","studyType":"Clinical Study"}],"tags":[{"label":"gitoformate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C01AA09","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"formiloxin","offLabel":[],"synonyms":["gitoformate","formiloxin","formiloxine","pentaformylgitoxin"],"timeline":[],"approvals":[],"brandName":"Formiloxin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"gitoformate","explanation":"Imagine your body's cells have locks on them, and the key to unlocking these locks is a specific molecule. Formiloxin is designed to be that key, but the exact lock it fits into is still unknown. By binding to this target, Formiloxin may help to regulate various cellular processes and produce a therapeutic effect.","oneSentence":"Formiloxin is thought to work by interacting with a specific molecular target to produce a therapeutic effect.","technicalDetail":"The precise mechanism of action of Formiloxin involves the binding of the gitoformate molecule to a specific protein or receptor, leading to a cascade of downstream effects that ultimately result in the desired therapeutic outcome."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1296","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GITOFORMATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:57:27.905581","biosimilars":[],"competitors":[{"drugName":"acetyldigitoxin","drugSlug":"acetyldigitoxin","fdaApproval":"1975-04-24","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"digitoxin","drugSlug":"digitoxin","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"digoxin","drugSlug":"digoxin","fdaApproval":"1975-10-24","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"deslanoside","drugSlug":"deslanoside","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"gitoformate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acetyldigitoxin","brandName":"acetyldigitoxin","genericName":"acetyldigitoxin","approvalYear":"1975","relationship":"same-class"},{"drugId":"digitoxin","brandName":"digitoxin","genericName":"digitoxin","approvalYear":"","relationship":"same-class"},{"drugId":"digoxin","brandName":"digoxin","genericName":"digoxin","approvalYear":"1975","relationship":"same-class"},{"drugId":"deslanoside","brandName":"deslanoside","genericName":"deslanoside","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"B69U29O7J9","CHEBI":"CHEBI:135896","INN_ID":"3117","UMLSCUI":"C0070285","ChEMBL_ID":"CHEMBL2103959","KEGG_DRUG":"D07147","DRUGBANK_ID":"DB13537","PUBCHEM_CID":"20055283","MESH_SUPPLEMENTAL_RECORD_UI":"C008785"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C01AA09","allCodes":["C01AA09"]},"biosimilarFilings":[],"recentPublications":[{"date":"1987 Dec","pmid":"3449065","title":"[Postprandial delay of drug absorption in a gitoformate model].","journal":"Arzneimittel-Forschung"},{"date":"1984 May-Jun","pmid":"6542412","title":"[Plasma levels of gitoxin (by RIA and rubidium-86 uptake) and systolic time after treatment with a single dose of gitoformate].","journal":"Cardiologia (Rome, Italy)"},{"date":"1984","pmid":"6541927","title":"[Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency].","journal":"Arzneimittel-Forschung"},{"date":"1981","pmid":"7185409","title":"[Pharmacokinetics and pharmacodynamics of gitoformate in subjects with atrial fibrillation].","journal":"Bollettino della Societa italiana di cardiologia"},{"date":"1981","pmid":"7185408","title":"[Pharmacokinetics of gitoformate in subjects with renal insufficiency under dialysis treatment].","journal":"Bollettino della Societa italiana di cardiologia"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formiloxin, also known as GITOFORMATE, is a small molecule drug in the gitoformate class. Its exact target and mechanism of action are unknown, but it is being developed for potential therapeutic applications. The commercial status of Formiloxin is unclear, with no information available on FDA approval, patent status, or generic manufacturers. Further research is needed to determine its efficacy and safety profile. As a result, key safety considerations and approved indications are currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}